U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The U.S. FDA, the Parenteral Drug Association and the respective local Chinese FDA jointly held the first education seminar on quality systems in Shanghai and Beijing in late April
You may also be interested in...
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 1 of 2)
U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed (PharmAsia News, Dec. 17, 2007). PharmAsia News' China and Australia bureaus spoke recently to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part one of a two-part interview; please look for part two in an upcoming issue of PharmAsia News.